MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Retained Earnings 2011-2026 | BHC
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.78 B | -9.19 B | -8.96 B | -8.01 B | -7.45 B | -5.66 B | -2.72 B | -5.13 B | -2.75 B | -2.36 B | -3.28 B | -2.37 B | -2.03 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 B | -9.78 B | -5.36 B |
Quarterly Retained Earnings Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.83 B | -9.84 B | -9.78 B | -9.74 B | -9.36 B | -9.39 B | -9.19 B | -8.78 B | -9.18 B | -9.03 B | -8.96 B | -9.03 B | -9.22 B | -8.96 B | -8.01 B | -8.01 B | -8.01 B | -8.01 B | -7.45 B | -7.45 B | -7.45 B | -7.45 B | -5.66 B | -5.66 B | -5.66 B | -5.66 B | -2.72 B | -2.72 B | -2.72 B | -2.72 B | -5.13 B | -5.13 B | -5.13 B | -5.13 B | -2.75 B | -2.75 B | -2.75 B | -2.75 B | -2.4 B | -2.36 B | -2.36 B | -2.36 B | -3.28 B | -3.28 B | -3.28 B | -3.28 B | -2.37 B | -2.37 B | -2.37 B | -2.37 B | -2.03 B | -2.03 B | -2.03 B | -2.03 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 B | -9.84 B | -5.51 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.07 | -0.47 % | $ 115 M |  Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Harrow Health
HROW
|
-157 M | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.62 | -0.57 % | $ 1.36 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.55 | -0.97 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.52 | -5.26 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.86 | -4.67 % | $ 377 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 11.92 | 1.24 % | $ 847 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.38 | -3.17 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
-3.68 B | $ 11.38 | -7.97 % | $ 1.58 B | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.53 | 0.33 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.99 | -3.47 % | $ 244 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.76 | -2.66 % | $ 3.43 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.37 | -2.97 % | $ 4.55 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 15.09 | -3.89 % | $ 18.1 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.79 | -2.48 % | $ 3.41 M | USA |